Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Novavax Vaccine

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate.

Leveraging Novavax’s recombinant, protein-based nanoparticle technology and Matrix-M adjuvant, the vaccine candidate induced robust immune responses in nonhuman primates after either single—or two-dose intranasal (IN) or intramuscular (IM) administration.